Discovering the Shared and Everlasting
Future of Humans and Animals

ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.

What’s New

logo

event

Sharing of Internationalization Strategies at Klifovet's 20th Anniversary Commemoration

July 21, 2017

ZENOAQ would like to take this opportunity to congratulate Klifovet on its 20th anniversary, and wishes Klifovet many more years of service to the industry. ZENOAQ was recently invited by Klifovet, a veterinary CRO based in Germany, as a guest speaker during an event in commemoration of Klifovet's 20th anniversary, held in Munich on the 29 and 30 of June, 2017. Dr. Mark Micallef, Executive Director of International Business at ZENOAQ, shared his insights on "Internationalization strategies of an innovative company: A Japanese way". Dr. Micallef also introduced ZENOAQ and the company's potential in the global arena. A warm response was received from the audience and ZENOAQ would like to thank all the participants for their interest, and especially Klifovet's CEO, Dr. Klaus Hellmann for inviting us to this prestigious event.

Klifovet170629.jpg

event

Sharing the latest information on Japanese Animal Health Market during the Animal Health Investment Europe in London (2017)

March 16, 2017

ZENOAQ was invited as a guest speaker during the Animal Health Investment Europe in London, which was held on 22 and 23 February 2017. Dr. Mark Micallef, Executive Director of International Business, provided updates on the latest trends of the animal health market in Japan. Our sincerest gratitude to all participants for your attendance and interest. Please feel free to contact us via our official company website for more details.

picture.jpg
Dr. Mark Micallef, Executive Director of International Business, addressing participants during the forum.

news

Allermmune® HDM Registered in South Korea

February 01, 2017

Allermmune® HDM is the first-of-its-kind desensitization therapy (allergen-specific immunotherapy) containing recombinant Der f 2, which is one of the major allergens in house dust mite (HDM)-induced canine atopic dermatitis (cAD).

Allermmune HDM has been proven to be safe and highly effective in clinical studies involving pet dogs diagnosed with HDM-induced cAD and positive for Der f 2 specific serum IgE. This product has been registered and sold in Japan since 2014. Allermmune HDM is expected to be launched in South Korea in April 2017 through our local distributor, ESTIEN Corp.

news

No Impact on ZENOAQ's Business Despite the Magnitude 7.4 Earthquake on November 22

November 22, 2016

ZENOAQ announces that its business was not affected by the earthquake that took place this morning (November 22). We appreciate your concern and all the warm messages.

Archive